If men felt the way we do two weeks of the month, scientists would be working around the clock to solve their suffering. But ...

YUFLYMA® (adalimumab-aaty), and its unbranded version, are now approved for two additional pediatric indications - adolescent hidradenitis suppurativa (HS) and ...

Patients suspecting they have multiple sclerosis (MS) are encountering significant delays in accessing specialist care, with ...

By the time patients start seeking care for multiple sclerosis (MS), the disease has already been damaging their brains for ...

Trageting abnormal brain cells linked to chronic inflammation may be key to treating people with progressive forms of MS, a ...

With over 1 million Americans affected by multiple sclerosis (MS), we wanted to learn more about its symptoms, particularly ...

Multiple sclerosis, which affects around one in 500 people in Switzerland, is an autoimmune disease in which immune cells ...

Updates in relapsing-remitting MS from ECTRIMS 2025 examine lifestyle interventions, anti-CD20 therapies, efficacy of fenebrutinib, and bone marrow transplantation as an effective long-term treatment.

A well-established diabetes drug alleviated brain inflammation in a female mouse model of multiple sclerosis, suggesting the ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new long-term data highlighting the sustained survival benefits of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 ...

YUFLYMA® (adalimumab-aaty), and its unbranded version, are now approved for two additional pediatric indications - adolescent hidradenitis suppurativa (HS) and pediatric uveitis (UV), in the ...